Kineta Acquires Novel Drug Candidates From Airmid For Potential Treatment Of Multiple Sclerosis, Type 1 Diabetes And Other Autoimmune Diseases

Main Category: Multiple Sclerosis
Also Included In: Diabetes;  Immune System / Vaccines
Article Date: 07 Jul 2009 - 6:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Kineta, Inc. of Seattle and Airmid Incorporated of Redwood City, CA jointly announce an agreement in which a Kineta subsidiary has acquired exclusive commercial rights to a portfolio of novel therapeutic compounds from Airmid. The array of compounds holds extraordinary potential for the treatment of multiple sclerosis, type 1 diabetes mellitus and numerous other autoimmune diseases.

"This transaction is a significant milestone for Airmid. It places our peptidic Kv1.3 blockers into the very capable hands of Kineta's drug development team, sets Airmid on a path to provide substantial return-on-investment for our shareholders, and provides funding to enhance the value of Airmid's retained assets," said George Miljanich, Ph.D., CEO of Airmid. Under the terms of the deal, Airmid will receive upfront payments, development, regulatory and commercial milestones as well as sales royalties.

Airmid founder, K. George Chandy, MD, Ph.D., also applauded the announcement: "Kineta possesses both the scientific capacity and the track record of success necessary to advance these promising therapeutics toward the goal of conquering multiple devastating autoimmune diseases."

Following today's agreement, Kineta One, LLC (a subsidiary of Kineta, Inc.) will aggressively pursue additional preclinical studies on a lead compound. The company intends to file an investigational new drug (IND) application with the FDA and begin clinical trials in 2010. "We are very excited to move forward. Dr. Chandy is an extraordinary scientist who has made an exceptional contribution to the scientific field of autoimmune disease. He will remain an integral advisor to our scientific team," said Kineta President and CEO, Charles Magness, Ph.D.

Dr. Chandy, Airmid co-founder Dr. Michael Cahalan and their colleagues at the University of California have spent more than two decades identifying and characterizing ion channels and their role in immune cell function under normal conditions and in autoimmune diseases. Dr. Chandy and his collaborators-Dr. Michael Pennington, Dr. Christine Beeton, Dr. Heike Wulff and Dr. Ray Norton-are credited with discovering an array of novel autoimmune compounds which were later patented. Together they founded Airmid Incorporated. A professor of physiology and biophysics at the University of California, Irvine, Dr. Chandy is an internationally recognized authority on mechanisms of autoimmunity and the role of ion channels in autoimmune disease.

The novel class of compounds acquired by Kineta One, LLC today includes potent and highly specific Kv1.3 potassium channel blockers derived from venom of the Caribbean sea anemone. They are designed to suppress activation of effector memory T cells which are important mediators of inflammation and tissue damage in MS, type 1 diabetes and other autoimmune diseases. These compounds have been shown to significantly reverse disease in animal models of multiple sclerosis and rheumatoid arthritis, and also have potential against a number of other autoimmune diseases controlled by effector memory T cells. Animal models also have demonstrated that efficacy is achieved without the generalized immunosuppression that occurs in competing therapies.

Source
Kineta, Inc.
Airmid Inc.